Antimicrobial resistance, especially pneumococcal resistance to macrolide antibiotics, or potential safety concerns of commonly used antibiotics result in underserving certain patients with CABP.  A systemic pleuromutilin antibacterial may be a treatment alternative for these underserved patients. 

This content is developed exclusively by or on behalf of the industry sponsor through a third party and is not reviewed by Pri-Med. The content and opinions expressed are those of the sponsor or presenters and may not reflect the views of Pri-Med. 



Christian Sandrock, MD, MPH, FCCP

Director of Critical Care, UC Davis Health

Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.